Usefulness of biomarkers of sepsis in the ICU;Utilité des biomarqueurs du sepsis en réanimation

Revue Medicale Suisse

Volumn 7, Issue 321, 2011, Pages 2430-2434

  Jolivet, P ^a   Christen, G ^b   Seematter, G ^b   Que, Y A ^a   Eggimann, P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hopital Riviera   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GROWTH ARREST SPECIFIC PROTEIN 6; IMMUNOLOGIC AGENT; LITHOSTATHINE; PROCALCITONIN; PHARMACOLOGICAL BIOMARKER;

ANTIBIOTIC THERAPY; CRITICALLY ILL PATIENT; DISEASE COURSE; DISEASE SEVERITY; DRUG EXPOSURE; DRUG TREATMENT FAILURE; HUMAN; IMMUNOTHERAPY; INTENSIVE CARE UNIT; MORTALITY; PROGNOSIS; REVIEW; SEPSIS; SEPTIC SHOCK; TREATMENT DURATION; BLOOD; HOSPITALIZATION; INFECTION; INTENSIVE CARE; METHODOLOGY; PERSONALIZED MEDICINE; PREDICTIVE VALUE;

BIOLOGICAL MARKERS; BIOMARKERS, PHARMACOLOGICAL; HUMANS; INDIVIDUALIZED MEDICINE; INFECTION; INTENSIVE CARE; INTENSIVE CARE UNITS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEPSIS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC;

EID: 84857153455     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
2. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP. High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 immunoglobulin study group. Am J Med 1991;91:23-9.
3. Linder A, Christensson B, Herwald H, Bjorck L, Akesson P. Heparin-binding protein: An early marker of circulatory failure in sepsis. Clin Infect Dis 2009;49:1044-50.
4. Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: A prospective, multicenter, observational study. Am J Respir Crit Care Med 2009;180:861-6.
5. Lu Q, Rouby JJ, Laterre PF, et al. Pharmacokinetics and safety of panobacumab: Specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother 2011;66:1110-6.
6. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial. JAMA 2009;301:2445-52.
7. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008;359:1766-77.
8. Roger T, Lugrin J, Le RD, et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011;117:1205-17.
9. &z.ast; Vincent JL, Donadello K, Schmit X. Biomarkers in the critically ill patient: C-reactive protein. Crit Care Clin 2011;27:241-51.
10. &z.ast;&z.ast; Pierrakos C, Vincent JL. Sepsis biomarkers: A review. Crit Care 2010;14:R15.
11. &z.ast; Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164:396-402.
12. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations. Crit Care Med 2008;36:941-52.
13. Baumgartner JD, Bula C, Vaney C, et al. A novel score for predicting the mortality of septic shock patients. Crit Care Med 1992;20:953-60.
14. Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Crit Care Med 2011;39:2048-58.
15. Ekman C, Linder A, Akesson P, Dahlback B. Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes. Crit Care 2010;14:R158.
16. Boeck L, Eggimann P, Smyrnios N, et al. The sequential organ failure assessment score and copeptin for predicting survival in ventilator-associated pneumonia. J Crit Care 2011. Epub ahead of print.
17. Boeck L, Graf R, Eggimann P, et al. Pancreatic stone protein: A marker of organ failure and outcome in ventilator-associated pneumonia. Chest 2011;140:925-32.
18. Que YA, Eggimann P, Liaudet L, Chiolero R. Lausanne cohort of septic patients as an opportunity to develop multidisciplinary research within the Swiss latin network of intensive care medicine. Rev Med Suisse 2008;4:2686-90.
19. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010;8:575-87.
20. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am J Respir Crit Care Med 2008;177:498-505. (Pubitemid 351442188)
21. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: A randomised study. Eur Respir J 2009;34:1364-75.
22. &z.ast; Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial. Lancet 2010;375:463-74.
23. &z.ast;&z.ast; Luyt CE, Combes A, Trouillet JL, Chastre J. Value of the serum procalcitonin level to guide antimicrobial therapy for patients with ventilator-associated pneumonia. Semin Respir Crit Care Med 2011;32:181-7.
24. Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2010;38:2229-41.
25. Reinhart K, Hartog CS. Biomarkers as a guide for antimicrobial therapy. Int J Antimicrob Agents 2010;36:S17-S21.